The congressional sponsor of legislation that would require hospitals and potentially other covered entities to publicly report their 340B revenue, [...] …
Category: Trade Association
The boards of directors of health centers need to take on a bigger advocacy role in support of the 340B [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The nation’s largest hospital advocacy organization urged legislators to drop a provision from draft legislation that would exclude generic injectables [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
An alliance led by a powerful drug industry trade group and community health center organization that is pushing for 340B [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The lead plaintiff in the legal battle that resulted in Medicare proposing an unusual lump sum payback for hospitals’ lost [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Congress should let for-profit hospitals into the 340B drug pricing program as “a long overdue evolutionary step” that will advance [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The creation of a claims clearinghouse and increasing both the funding and authority of the federal agency overseeing the 340B [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The National Association of Community Health Centers (NACHC) announced yesterday that its board has chosen Dr. Kyu Rhee, now CVS [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The American Hospital Association purchased a large ad in The Wall Street Journal print edition Tuesday touting the 340B program’s benefits and saying, “It is in the best interest of all to keep the 340B program strong.”
The quarter-page
…
340B hospital and pharmacy groups have launched another digital ad campaign touting the 340B program’s benefits to policymakers. It comes amid a rise in negative messages about 340B from the drug industry and conservative think tanks and the publication of
…